Thalidomide for treatment of intestinal involvement of juvenile-onset Behçet disease

Inflammatory Bowel Diseases

Volumn 14, Issue 3, 2008, Pages 396-400

  Yasui, Kozo ^a   Uchida, Noriko ^a   Akazawa, Yohei ^a   Nakamura, Shinichi ^a   Minami, Isaki ^a   Amano, Yoshiro ^a   Yamazaki, Takashi ^b  

^a NAGANO RED CROSS HOSPITAL   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Inflammatory bowel diseases; Innate immunity; Macrophage; Neutrophil

Indexed keywords

AZATHIOPRINE; COLCHICINE; CYCLOSPORIN; MERCAPTOPURINE; METHOTREXATE; PENTOXIFYLLINE; PREDNISOLONE; STEROID; THALIDOMIDE;

ADOLESCENT; ADULT; ARTICLE; BEHCET DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTEROPATHY; FEMALE; HUMAN; INSOMNIA; JUVENILE; LOADING DRUG DOSE; LOW BACK PAIN; LOW DRUG DOSE; MALE; NERVE CONDUCTION DISORDER; NEUROTOXICITY; ONSET AGE; OSTEOPOROSIS; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VERTEBRA FRACTURE;

ADOLESCENT; ADULT; BEHCET SYNDROME; C-REACTIVE PROTEIN; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; RETROSPECTIVE STUDIES; THALIDOMIDE;

EID: 41149125003     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20317     Document Type: Article

References (41)

1. Sakane T, Takeno M, Suzuki N, et al. Behçet's disease. N Engl J Med. 1999;341:1284-1291.
2. Fujikawa S, Suemitsu T. Behçet's disease in children: a nationwide retrospective survey in Japan. Acta Paediatr Jpn. 1997;39:285-289.
3. Yasui K, Komiyama A, Takabayashi Y, et al. Behçet's disease in children. J Pediatr. 1999;134:249-251.
4. Marshall SE. Behçet's disease. Best Pract Res Clin Rheumatol. 2004;18:291-311.
5. Everklioglu C. Current concepts in the etiology and treatment of Behçet's disease. Surv Ophthalmol. 2005;50:297-350.
6. Kume K, Hashiba T, Yoshikawa I, et al. Therapeutic experience of hyperbaric oxygenation in entero-Behcet syndrome. Am J Gastroenterol. 2001;96:1308-1309.
7. Yasui K, Misawa Y, Shimizu T, et al. Thalidomide therapy for juvenile-onset entero-Behçet disease. J Pediatr. 2003;143:692-694.
8. Dredge K, Marriot JB, Dalgleish AG. Immunological effects of thalidomide and its chemical and functional analogs. Crit Rev Immunol. 2002;22:425-437.
9. Annas GJ, Elias S. Thalidomide and the Titanic: reconstructing the technology tragedies of the twentieth century. Am J Public Health. 1999;89:98-101.
10. McBride WG. Thalidomide and congenital abnormalities. Lancet. 1961;1:1358.
11. Mellin GW, Katzenstein M. The saga of thalidomide. N Engl J Med. 1962;267:1184-1193.
12. Lentz W. Thalidomide and congenital abnormalities. Lancet. 1962;1:45.
13. Sheskin J. The treatment of lepra reaction in lepromatous leprosy. Int J Dermatol. 1980;19:318-322.
14. Wu JJ, Huang DB, Pang KR, et al. Thalidomide:dermatological indications, mechanisms of action and side-effects. Br J Dermatol. 2005;153:254-273.
15. Marriott JB, Muller G, Dalgleish AG. Thalidomide as an emerging immunotherapeutic agent. Immunol Today. 1999;20:538-540.
16. Ossandon A, Cassara EAM, Priori R, et al. Thalidomide: focus on its employment in rheumatic diseases. Clin Exp Rheumatol. 2002;20:709-718.
17. Lehman TJA, Striegel KH, Onel KB. Thalidomide therapy for recalcitrant systemic onset juvenile rheumatoid arthritis. J Pediatr. 2002;140:125-127.
18. Lehman TJA, Schechter SJ, Sundel RP, et al. Thalidomide for severe systemic onset juvenile rheumatoid arthritis: a multicenter study. J Pediatr. 2004;145:856-857.
19. Kaplan G, Thomas S, Fierer DS, et al. Thalidomide for the treatment of AIDS-associated wasting. AIDS Res Hum Retroviruses. 2000;16:1345-1355.
20. Cattelan AM, Trevenzoli M, Aversa SM. Recent advances in the treatment of AIDS-related Kaposi's sarcoma. Am J Clin Dermatol. 2002;3:451-462.
21. Bessis D, Guillot B, Monpoint S, et al. Thalidomide for systemic lupus erythematosus. Lancet. 1992;339:549-550.
22. Schoeman J F, Springer P, Ravenscroft A, et al. Adjunctive thalidomide therapy of childhood tuberculous meningitis: possible anti-inflammatory role. J Child Neurol. 2000;15:497-503.
23. Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. Ann Intern Med. 1998;128:443-450.
24. Ginsburg PM, Hanan I, Ehrenpreis ED. Treatment of severe esophageal Crohn's disease with thalidomide. Am J Gastroenterol. 2001;96:1305-1306.
25. Bariol C, Meagher AP, Vickers CR, et al. Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. J Gastroenterol Hepatol. 2002;17:135-139.
26. Bauditz J, Schachschal G, Wedel S, et al. Thalidomide for treatment of severe intestinal bleeding. Gut. 2004;53:609-612.
27. Shek LP, Lee YS, Lee BW, et al. Thalidomide responsiveness in an infant with Behçet's syndrome. Pediatrics. 1999;103:1295-1297.
28. Kari JA, Shah V, Dillon MJ. Behçet's disease in UK children: clinical features and treatment including thalidomide. Rheumatology. 2001;40:933-938.
29. Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med. 1991;173:699-703.
30. Marriott JB, Westby M, Dalgleish AG. The therapeutic potential of TNF-α inhibitors old and new. Drug Discov Today. 1997;2:273-282.
31. Baughman RP, Judson MA, Teirstein AS, et al. Thalidomide for chronic sarcoidosis. Chest. 2002;122:227-232.
32. Moreira AL, Sampaio EP, Zmuidzinas A, et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med. 1993;177:1675-1680.
33. Sampaio EP, Kaplan G, Miranda A, et al. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis. 1993;168:408-414.
34. Keifer JA, Guttridge DC, Ashburner BP, et al. Inhibition of NF-κB activity by thalidomide through suppression of IκB activity. J Biol Chem. 2001;276:22382-22387.
35. Barnes PJ, Karin M. Nuclear factor-kappa B: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336:1066-1071.
36. 2, but not that activated by ceralide, lipopolysaccharides, or phorbol ester. J Immunol. 2002;168:2644-2651.
37. Direskeneli H, Saruhan-Direskeneli G. The role of heat shock proteins in Behcet's disease. Clin Exp Rheumatol. 2003;21:S44-S48.
38. Grabstad H, Golbey R. Clinical experiences with thalidomide in patients with cancer. Clin Pharmacol Ther. 1965;6:298-302.
39. Olson KB, Hall TC, Horton J, et al. Thalidomide (N-phthaloylglutamidine) in the treatment of advanced cancer. Clin Pharmacol Ther. 1965;40:292-297.
40. Kawamura T, Miyaji C, Toyabe S, et al. Suppressive effect of antiulcer agents on granulocytes - a role for granulocytes in gastric ulcer formation. Digest Dis Sci. 2000;45:1786-1791.
41. Chajek-Shaul T, Pisanty S, Knobler H, et al. HLA-B51 may serve as an immunogenetic marker for a subgroup of patients with Behcet's syndrome. Am J Med. 1987;83:666-672.